Park Ha Biological Technology Co., Ltd. (PHH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Park Ha Biological Technology Co., Ltd. (PHH) has a cash flow conversion efficiency ratio of -0.112x as of June 2018. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-55.00 Million) by net assets ($489.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Park Ha Biological Technology Co., Ltd. net asset quality index to measure how much of total assets are equity-financed.
Park Ha Biological Technology Co., Ltd. - Cash Flow Conversion Efficiency Trend (1993–2024)
This chart illustrates how Park Ha Biological Technology Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PHH operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Park Ha Biological Technology Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Park Ha Biological Technology Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
-4.279x |
|
Intrasense
PA:ALINS
|
0.452x |
|
RENEWABLE VENTURES NORDIC
F:X72
|
0.056x |
|
Daesang Corp Preference Shares
KO:001685
|
0.058x |
|
Skin Elements Ltd
AU:SKN
|
-0.699x |
|
Green Packet Bhd
KLSE:0082
|
0.221x |
|
Sapura Resources Bhd
KLSE:4596
|
0.126x |
|
Oxford Nanopore Technologies Ltd
LSE:ONT
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Park Ha Biological Technology Co., Ltd. (1993–2024)
The table below shows the annual cash flow conversion efficiency of Park Ha Biological Technology Co., Ltd. from 1993 to 2024. For the full company profile with market capitalisation and key ratios, see PHH market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.51 Million | $960.47K | 0.638x | +410.27% |
| 2023-12-31 | $1.01 Million | $126.54K | 0.125x | -98.70% |
| 2022-12-31 | $150.28K | $1.44 Million | 9.598x | +1014.62% |
| 2021-12-31 | $-578.18K | $-497.86K | 0.861x | +372.88% |
| 2017-12-31 | $1.66 Billion | $303.00 Million | 0.182x | +339.76% |
| 2016-12-31 | $1.76 Billion | $73.00 Million | 0.041x | -29.85% |
| 2015-12-31 | $2.05 Billion | $121.00 Million | 0.059x | +942.98% |
| 2014-12-31 | $1.57 Billion | $-11.00 Million | -0.007x | -100.44% |
| 2013-12-31 | $1.69 Billion | $2.71 Billion | 1.603x | +21.72% |
| 2012-12-31 | $1.56 Billion | $2.06 Billion | 1.317x | -30.94% |
| 2011-12-31 | $1.46 Billion | $2.79 Billion | 1.907x | +279.11% |
| 2010-12-31 | $1.58 Billion | $-1.68 Billion | -1.065x | -224.80% |
| 2009-12-31 | $1.50 Billion | $1.28 Billion | 0.853x | -42.86% |
| 2008-12-31 | $1.27 Billion | $1.89 Billion | 1.493x | -12.49% |
| 2007-12-31 | $1.56 Billion | $2.66 Billion | 1.706x | +252.60% |
| 2006-12-31 | $1.55 Billion | $748.00 Million | 0.484x | +70.32% |
| 2005-12-31 | $3.22 Billion | $915.00 Million | 0.284x | -53.01% |
| 2004-12-31 | $4.15 Billion | $2.51 Billion | 0.605x | -35.09% |
| 2003-12-31 | $4.12 Billion | $3.84 Billion | 0.931x | +68.51% |
| 2002-12-31 | $2.87 Billion | $1.59 Billion | 0.553x | -33.14% |
| 2001-12-31 | $1.78 Billion | $1.47 Billion | 0.827x | +103.14% |
| 2000-12-31 | $1.87 Billion | $761.00 Million | 0.407x | -50.36% |
| 1999-12-31 | $1.63 Billion | $1.34 Billion | 0.820x | +65.35% |
| 1998-12-31 | $1.74 Billion | $861.70 Million | 0.496x | -18.23% |
| 1997-12-31 | $1.51 Billion | $918.24 Million | 0.606x | +259.22% |
| 1995-12-31 | $4.58 Billion | $772.68 Million | 0.169x | -22.56% |
| 1994-12-31 | $4.18 Billion | $910.92 Million | 0.218x | -80.58% |
| 1993-12-31 | $498.31 Million | $559.19 Million | 1.122x | -- |
About Park Ha Biological Technology Co., Ltd.
Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. The company operates in two segments, Product Sales and Franchise Service. It offers various products, such as basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance, and anti-aging under the Park Ha brand. It sells produ… Read more